ADMA Biologics' stock plummeted 24.01% in post-market trading on Wednesday, following the release of disappointing first-quarter financial results and the withdrawal of the company's long-term guidance.

The specialty biologics maker reported Q1 revenue of $114.5 million, significantly missing the analyst consensus estimate of $141.8 million. Adjusted net income for the quarter was $40.7 million, also falling short of expectations. The company attributed the revenue pressure primarily to a 54% year-over-year decline in BIVIGAM sales, driven by increased competition and distributor ordering variability.

In a move that heightened investor concerns, ADMA Biologics withdrew its long-term financial guidance, citing evolving competitive dynamics in the plasma-derived therapy and immune globulin market. While the company provided fiscal year 2026 revenue guidance of $530 million to $560 million, the removal of the longer-term outlook signaled uncertainty about future growth prospects amid heightened market competition.